At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 44 enrolled
Drug / intervention
Myfortic +1 moredrug
Likely dose
Myfortic 360 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Myfortic (Enteric-coated Mycophenolate Sodium) for the Treatment of Non-infectious Intermediate Uveitis - a Prospective, Controlled, Randomized Multicenter Trial
In Brief
A Phase 3 clinical trial evaluating Myfortic and Decortin for Uveitis, Intermediate. Completed, enrolled 44 participants across 5 sites.
Detailed Summary
The objective of this clinical trial is to evaluate the efficacy, safety and tolerability of enteric-coated mycophenolate sodium (Myfortic®) in combination with low-dose corticosteroids (Decortin H®) compared to a monotherapy with low-dose corticosteroids (Decortin H®) in subjects with chronic intraocular inflammation (non-infectious intermediate uveitis).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUveitis, Intermediate
CountriesGermany
CollaboratorsNovartis Pharmaceuticals, University Hospital Tuebingen
Timeline
Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMar 2010
First PostedMar 2010
Primary CompletionOct 2015
TodayJul 2026
First PostedMar 25, 2010
Enrollment StartMar 1, 2010
Primary CompletionOct 1, 2015
TodayJul 2, 2026
Enrollment to primary: 5.6 yearsPosted 16.3 years ago
Interventions
Myforticdrug
Myfortic 360 mg BID (during week 1) Myfortic 720 mg BID (from week 2 on) Maintenance dose Decortin 5mg/d
Decortindrug
Maintenance dose 5 mg/d